JPWO2022204228A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022204228A5 JPWO2022204228A5 JP2023558248A JP2023558248A JPWO2022204228A5 JP WO2022204228 A5 JPWO2022204228 A5 JP WO2022204228A5 JP 2023558248 A JP2023558248 A JP 2023558248A JP 2023558248 A JP2023558248 A JP 2023558248A JP WO2022204228 A5 JPWO2022204228 A5 JP WO2022204228A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- acceptable salt
- pharma
- collapse
- disease associated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 12
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 229940122522 Mineralocorticoid antagonist Drugs 0.000 claims 10
- 239000002394 mineralocorticoid antagonist Substances 0.000 claims 10
- 229960002256 spironolactone Drugs 0.000 claims 10
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims 10
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 claims 8
- 229960002430 atomoxetine Drugs 0.000 claims 8
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 6
- 239000003149 muscarinic antagonist Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 206010041235 Snoring Diseases 0.000 claims 4
- 208000001797 obstructive sleep apnea Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 2
- CBQGYUDMJHNJBX-OALUTQOASA-N (2S)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine Chemical compound CCOC1=CC=CC=C1O[C@@H](C=1C=CC=CC=1)[C@H]1OCCNC1 CBQGYUDMJHNJBX-OALUTQOASA-N 0.000 claims 2
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 claims 2
- BTBHLEZXCOBLCY-QGZVFWFLSA-N (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide Chemical compound C1([C@@H]2C(=C(C)NC=3C(C)=CN=C(C2=3)OCC)C(N)=O)=CC=C(C#N)C=C1OC BTBHLEZXCOBLCY-QGZVFWFLSA-N 0.000 claims 2
- NOSNHVJANRODGR-UHFFFAOYSA-N 1-(2-hydroxyethyl)-4-methyl-n-(4-methylsulfonylphenyl)-5-[2-(trifluoromethyl)phenyl]pyrrole-3-carboxamide Chemical compound CC=1C(C(=O)NC=2C=CC(=CC=2)S(C)(=O)=O)=CN(CCO)C=1C1=CC=CC=C1C(F)(F)F NOSNHVJANRODGR-UHFFFAOYSA-N 0.000 claims 2
- FKHYYOUFMJBLAF-UHFFFAOYSA-N 3-(3,3-dimethyl-1-phenyl-2-benzothiophen-1-yl)-n-methylpropan-1-amine Chemical compound S1C(C)(C)C2=CC=CC=C2C1(CCCNC)C1=CC=CC=C1 FKHYYOUFMJBLAF-UHFFFAOYSA-N 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- PBKZPPIHUVSDNM-WNHSNXHDSA-N canrenoic acid Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)CCC(O)=O)[C@@H]4[C@@H]3C=CC2=C1 PBKZPPIHUVSDNM-WNHSNXHDSA-N 0.000 claims 2
- 229960002823 canrenoic acid Drugs 0.000 claims 2
- 229960005057 canrenone Drugs 0.000 claims 2
- UJVLDDZCTMKXJK-WNHSNXHDSA-N canrenone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)C=C3C=C2)C)CC[C@@]11C)C[C@@]11CCC(=O)O1 UJVLDDZCTMKXJK-WNHSNXHDSA-N 0.000 claims 2
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 claims 2
- 239000002934 diuretic Substances 0.000 claims 2
- 230000001882 diuretic effect Effects 0.000 claims 2
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 claims 2
- 229960004845 drospirenone Drugs 0.000 claims 2
- CPBHSHYQQLFAPW-ZWKOTPCHSA-N edivoxetine Chemical compound COC1=CC=C(F)C=C1C[C@](O)([C@H]1OCCNC1)C1CCOCC1 CPBHSHYQQLFAPW-ZWKOTPCHSA-N 0.000 claims 2
- 229950003015 edivoxetine Drugs 0.000 claims 2
- 229960001208 eplerenone Drugs 0.000 claims 2
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 claims 2
- 229950006558 esaxerenone Drugs 0.000 claims 2
- 229950008247 esreboxetine Drugs 0.000 claims 2
- 229950004408 finerenone Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- MJRPHRMGEKCADU-JVLSTEMRSA-N lortalamine Chemical compound C12=CC(Cl)=CC=C2O[C@]23CCN(C)C[C@@H]2[C@H]1CC(=O)N3 MJRPHRMGEKCADU-JVLSTEMRSA-N 0.000 claims 2
- 229950004863 lortalamine Drugs 0.000 claims 2
- ADZYJDJNIBFOQE-RGKMBJPFSA-N mexrenone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 ADZYJDJNIBFOQE-RGKMBJPFSA-N 0.000 claims 2
- ITJNARMNRKSWTA-UHFFFAOYSA-N nisoxetine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=CC=C1OC ITJNARMNRKSWTA-UHFFFAOYSA-N 0.000 claims 2
- 229950004211 nisoxetine Drugs 0.000 claims 2
- 229960002748 norepinephrine Drugs 0.000 claims 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 2
- RRHHMFQGHCFGMH-LAPLKBAYSA-N prorenone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)C=C3[C@H]3C[C@H]32)C)CC[C@@]11C)C[C@@]11CCC(=O)O1 RRHHMFQGHCFGMH-LAPLKBAYSA-N 0.000 claims 2
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 claims 2
- 229960003770 reboxetine Drugs 0.000 claims 2
- 201000002859 sleep apnea Diseases 0.000 claims 2
- LJBBMCNHIUJBDU-UHFFFAOYSA-N talopram Chemical compound O1C(C)(C)C2=CC=CC=C2C1(CCCNC)C1=CC=CC=C1 LJBBMCNHIUJBDU-UHFFFAOYSA-N 0.000 claims 2
- 229950007352 talopram Drugs 0.000 claims 2
- 229950002139 talsupram Drugs 0.000 claims 2
- BRPOADLGOFPKKJ-UHFFFAOYSA-N tandamine Chemical compound C12=CC=CC=C2N(CC)C2=C1CCSC2(C)CCN(C)C BRPOADLGOFPKKJ-UHFFFAOYSA-N 0.000 claims 2
- 229950006964 tandamine Drugs 0.000 claims 2
- 229960001255 viloxazine Drugs 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 1
- -1 aparalenone Chemical compound 0.000 claims 1
- 229950009097 apararenone Drugs 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- AZNHWXAFPBYFGH-UHFFFAOYSA-N n-[4-(4-fluorophenyl)-2,2-dimethyl-3-oxo-1,4-benzoxazin-7-yl]methanesulfonamide Chemical compound O=C1C(C)(C)OC2=CC(NS(C)(=O)=O)=CC=C2N1C1=CC=C(F)C=C1 AZNHWXAFPBYFGH-UHFFFAOYSA-N 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163165342P | 2021-03-24 | 2021-03-24 | |
| US63/165,342 | 2021-03-24 | ||
| PCT/US2022/021462 WO2022204228A1 (en) | 2021-03-24 | 2022-03-23 | Methods and compositions for treating sleep apnea |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024511091A JP2024511091A (ja) | 2024-03-12 |
| JP2024511091A5 JP2024511091A5 (https=) | 2025-04-01 |
| JPWO2022204228A5 true JPWO2022204228A5 (https=) | 2025-04-01 |
Family
ID=81388916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023558248A Pending JP2024511091A (ja) | 2021-03-24 | 2022-03-23 | 睡眠時無呼吸を治療するための方法及び組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240173337A1 (https=) |
| EP (1) | EP4313153A1 (https=) |
| JP (1) | JP2024511091A (https=) |
| KR (1) | KR20230159462A (https=) |
| CN (1) | CN117062626A (https=) |
| AU (1) | AU2022245235A1 (https=) |
| BR (1) | BR112023019256A2 (https=) |
| CA (1) | CA3212035A1 (https=) |
| CL (1) | CL2023002824A1 (https=) |
| CO (1) | CO2023012587A2 (https=) |
| CR (1) | CR20230457A (https=) |
| GE (1) | GEAP202416361A (https=) |
| IL (1) | IL307186A (https=) |
| MX (1) | MX2023011213A (https=) |
| WO (1) | WO2022204228A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119789855A (zh) * | 2022-09-02 | 2025-04-08 | 爱普宁公司(特拉华) | 治疗睡眠呼吸暂停的方法和组合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3746126B1 (en) * | 2018-01-30 | 2024-07-31 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea or simple snoring |
| EP4635514A3 (en) * | 2019-02-08 | 2025-12-24 | The Brigham & Women's Hospital, Inc. | Methods and compositions for treating sleep apnea |
| JP2023520455A (ja) * | 2020-04-02 | 2023-05-17 | アプニメッド，インコーポレイテッド（デラウェア） | 睡眠時無呼吸を治療するための方法および組成物 |
-
2022
- 2022-03-23 GE GEAP202416361A patent/GEAP202416361A/en unknown
- 2022-03-23 CR CR20230457A patent/CR20230457A/es unknown
- 2022-03-23 CA CA3212035A patent/CA3212035A1/en active Pending
- 2022-03-23 EP EP22719398.4A patent/EP4313153A1/en active Pending
- 2022-03-23 CN CN202280024023.9A patent/CN117062626A/zh active Pending
- 2022-03-23 BR BR112023019256A patent/BR112023019256A2/pt unknown
- 2022-03-23 KR KR1020237034335A patent/KR20230159462A/ko active Pending
- 2022-03-23 US US18/283,303 patent/US20240173337A1/en active Pending
- 2022-03-23 AU AU2022245235A patent/AU2022245235A1/en active Pending
- 2022-03-23 IL IL307186A patent/IL307186A/en unknown
- 2022-03-23 WO PCT/US2022/021462 patent/WO2022204228A1/en not_active Ceased
- 2022-03-23 MX MX2023011213A patent/MX2023011213A/es unknown
- 2022-03-23 JP JP2023558248A patent/JP2024511091A/ja active Pending
-
2023
- 2023-09-22 CL CL2023002824A patent/CL2023002824A1/es unknown
- 2023-09-22 CO CONC2023/0012587A patent/CO2023012587A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023139000A5 (https=) | ||
| JP2008535867A5 (https=) | ||
| AU2010237120B8 (en) | Method for on-demand contraception | |
| JP2024112848A (ja) | デクスメデトミジンを含むフィルム製剤、及びその作製方法 | |
| TWI522100B (zh) | 含有納布啡（ｎａｌｂｕｐｈｉｎｅ）之藥學組成物及其用途 | |
| JP2015512406A5 (https=) | ||
| JP2009536176A5 (https=) | ||
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| JP2013529665A5 (https=) | ||
| CN101291663A (zh) | 预防和治疗睡眠呼吸障碍的方法和工具 | |
| TW201834654A (zh) | 包含ｔａｓｋ－１與ｔａｓｋ－３通道抑制劑之醫藥劑型及其用於呼吸病症治療之用途 | |
| JP2025084754A5 (https=) | ||
| JP2022504181A5 (https=) | ||
| JP2008533127A5 (https=) | ||
| JP5362151B2 (ja) | Ｐｇｄ２拮抗剤及びヒスタミン拮抗剤からなるアレルギー性鼻炎治療用医薬 | |
| CN100558358C (zh) | 唑尼沙胺在制备用于治疗或预防阻塞性睡眠呼吸暂停的药物中的应用 | |
| BR112019027286B1 (pt) | Composição de dissolução oral de melatonina com agente acidificante que torna melatonina solúvel em saliva | |
| JP2009535409A (ja) | 即効性ジクロフェナク−オピオイド組成物に基づく急性疼痛医薬 | |
| TW200927118A (en) | Treatment of vasomotor symptoms | |
| JP2008533022A5 (https=) | ||
| JPWO2022204228A5 (https=) | ||
| CN105073098A (zh) | 包含选择性孕酮受体调节剂的共微粉化产物 | |
| CN112672743A (zh) | 肝病瘙痒症状的治疗 | |
| JP2008509147A5 (https=) | ||
| CN101663036B (zh) | 4-环丙基甲氧基-n-(3,5-二氯代-1-氧代-4-吡啶-4-基)-5-(甲氧基)吡啶-2-甲酰胺用于治疗颅脑创伤的用途 |